Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 1
2006 3
2007 2
2008 5
2009 3
2010 1
2012 4
2013 2
2016 1
2017 1
2019 3
2020 5
2021 5
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, Karasaki T, Moore DA, Salgado R, Sivakumar M, Young G, Molina-Arcas M, de Carné Trécesson S, Anastasiou P, Fendler A, Au L, Shepherd STC, Martínez-Ruiz C, Puttick C, Black JRM, Watkins TBK, Kim H, Shim S, Faulkner N, Attig J, Veeriah S, Magno N, Ward S, Frankell AM, Al Bakir M, Lim EL, Hill MS, Wilson GA, Cook DE, Birkbak NJ, Behrens A, Yousaf N, Popat S, Hackshaw A; TRACERx Consortium; CAPTURE Consortium; Hiley CT, Litchfield K, McGranahan N, Jamal-Hanjani M, Larkin J, Lee SH, Turajlic S, Swanton C, Downward J, Kassiotis G. Ng KW, et al. Among authors: molina arcas m. Nature. 2023 Apr;616(7957):563-573. doi: 10.1038/s41586-023-05771-9. Epub 2023 Apr 12. Nature. 2023. PMID: 37046094 Free PMC article.
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.
Boumelha J, de Carné Trécesson S, Law EK, Romero-Clavijo P, Coelho MA, Ng KW, Mugarza E, Moore C, Rana S, Caswell DR, Murillo M, Hancock DC, Argyris PP, Brown WL, Durfee C, Larson LK, Vogel RI, Suárez-Bonnet A, Priestnall SL, East P, Ross SJ, Kassiotis G, Molina-Arcas M, Swanton C, Harris R, Downward J. Boumelha J, et al. Among authors: molina arcas m. Cancer Res. 2022 Oct 4;82(19):3435-3448. doi: 10.1158/0008-5472.CAN-22-0325. Cancer Res. 2022. PMID: 35930804 Free PMC article.
Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.
Mugarza E, van Maldegem F, Boumelha J, Moore C, Rana S, Llorian Sopena M, East P, Ambler R, Anastasiou P, Romero-Clavijo P, Valand K, Cole M, Molina-Arcas M, Downward J. Mugarza E, et al. Among authors: molina arcas m. Sci Adv. 2022 Jul 22;8(29):eabm8780. doi: 10.1126/sciadv.abm8780. Epub 2022 Jul 20. Sci Adv. 2022. PMID: 35857848 Free PMC article.
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J. Coelho MA, et al. Among authors: molina arcas m. Immunity. 2017 Dec 19;47(6):1083-1099.e6. doi: 10.1016/j.immuni.2017.11.016. Epub 2017 Dec 12. Immunity. 2017. PMID: 29246442 Free PMC article.
Nucleoside transporter proteins.
Molina-Arcas M, Casado FJ, Pastor-Anglada M. Molina-Arcas M, et al. Curr Vasc Pharmacol. 2009 Oct;7(4):426-34. doi: 10.2174/157016109789043892. Curr Vasc Pharmacol. 2009. PMID: 19485885 Review.
Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
Boumelha J, Molina-Arcas M, Downward J. Boumelha J, et al. Among authors: molina arcas m. Clin Cancer Res. 2023 Dec 15;29(24):5012-5020. doi: 10.1158/1078-0432.CCR-22-3655. Clin Cancer Res. 2023. PMID: 37581538 Free PMC article.
The Potency of a KRAS Silent Variant.
Molina-Arcas M, Downward J. Molina-Arcas M, et al. N Engl J Med. 2022 Jun 30;386(26):2523-2525. doi: 10.1056/NEJMcibr2202981. N Engl J Med. 2022. PMID: 35767444 No abstract available.
Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110α.
Ismail M, Martin SR, George R, Houghton F, Kelly G, Chaleil RAG, Anastasiou P, Wang X, O'Reilly N, Federico S, Joshi D, Nagaraj H, Cooley R, Hui NS, Molina-Arcas M, Hancock DC, Tavassoli A, Downward J. Ismail M, et al. Among authors: molina arcas m. Sci Rep. 2023 Feb 2;13(1):1889. doi: 10.1038/s41598-023-28756-0. Sci Rep. 2023. PMID: 36732563 Free PMC article.
43 results